WCCT Global Adds Smoking Rooms to Phase 1 Clinical Unit

April 29, 2019

Cypress, CA. April 29, 2019/ iReach-PRNewswire/ — WCCT Global, Inc., a multisite, full-service early phase contract research organization (CRO) for pharmaceutical, biotechnology and medical device industries, announced today that smoking rooms have been added to their 75,000 ft2 Phase 1 Clinical Unit in Cypress, CA. The rooms are fully licensed and compliant for medical research with all state and local regulations, and are designed to facilitate accurate testing to produce optimal results.

 

WCCT’s 850 ft2 smoking rooms use a controlled air supply system with a 3500 CFM exhaust rate for static extraction of contaminated air. The fully enclosed, isolated air venting system maintains the highest quality of standards with micro-filtered air intake lines which act as additional measures against cross-contamination. The unit has a synthetic dual membrane coating on the walls, providing a further barrier between procedure rooms. Antechambers are located adjacent to each testing room and provide a fully enclosed ventilation system.

 

The smoking rooms were designed to accommodate combustible and non-combustible nicotine products, and each room is temperature controlled providing complete control over the dosing room environment. WCCT purposely designed the modular unit in a location allowing for additional expansion in the future, and all structures and processes are compliant with the California Clean Air Act, California Labor Code 6404.5, and California AB 13.

 

In the design process, WCCT used models and tactics implemented by Law Enforcement agencies to strategically implement safe handling procedures for combustible and toxic gasses in confined environments. By engineering the rooms and ventilation systems for optimal air-flow, WCCT can completely cycle through the air in each testing room in approximately 60 seconds. In comparison, recreational cigar lounges complete this cycle in an average of 5 minutes. The increased speed of the cycle creates a contaminate-free and stable testing environment for a wide range of aerosol products, including nicotine delivery systems, vaping devices, and inhalant medications.

 

WCCT has conducted several tobacco trials and this facility enhancement provides expanded capabilities to conduct a variety of additional trials in combustible and electronic nicotine delivery systems (ENDS). The unit will also serve as dosing rooms for clinical trials testing aerosolized and inhaled products. WCCT is excited to conduct more related studies at its Phase 1 clinical unit and facilitate research that continues to promote global health.